PARIS, Sept. 6, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, will present two posters on its OncoMimics™ pipeline at the European Society for Medical Oncology (ESMO) Congress 2022, which will be held September 9-13 in Paris, France. The posters will focus on two clinical trials evaluating EO2401 to treat patients with recurrent glioblastoma (ROSALIE) and adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP) (SPENCER).
Details on Enterome's poster presentations
ROSALIE study
Title: EO2401 (EO) therapeutic vaccine for patient (pts) with recurrent glioblastoma (GB): phase 1/2 ROSALIE study
Authors: D. Reardon et al
Abstract number: 1223
Category: CNS tumours
Date: Saturday September 10th , 2022
Key highlights :
SPENCER study
Title: EO2401 (EO) therapeutic vaccine for patient (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): phase 1/2 SPENCER study
Authors: E. Baudin et al
Abstract number: 3149
Category: Adrenal cancer
Presenter: Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)
Date/Time: Oral Presentation- Monday September 12th, 2022 at 9.40 am CEST
Key highlights:
Contacts
ENTEROME | MEDIA RELATIONS |
Guillaume Bayre Head of External Communications Tel; +33 (0)1 76 21 58 15 | Sylvie Berrebi / Mark Swallow / David Dible MEDiSTRAVA Consulting Tel. +44 (0) 203 928 6900 |
About Enterome
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome's pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform allowing to uncover new biological insights from millions of gut bacteria proteins in constant cross-talk with the human body.
Enterome's potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones, or cytokines.
Enterome is presently advancing two pipelines of drug candidates, OncoMimics™ and EndoMimics™, which have the potential to address cancer, inflammatory and autoimmune diseases, respectively:
Enterome employs 65 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life science investors and more than €100 million from pharmaceutical partnerships.
For more information, please visit the company's website at: www.enterome.com
SOURCE Enterome